1. TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors

   • Natalia Sauer
   • Natalia Janicka
   • Katarzyna Karłowicz-Bodalska

   Review Open access 11 August 2023 Pages: 3405 - 3425

   

2. Cancer management during the COVID-19 world pandemic

   • Navid Sobhani
   • Giuseppina Mondani
   • Daniele Generali

   Review 29 August 2023 Pages: 3427 - 3444

   

3. Radiation-associated secondary malignancies: a novel opportunity for applying immunotherapies

   • Tavus Atajanova
   • Md Mahfuzur Rahman
   • Zachary S. Morris

   Review 02 September 2023 Pages: 3445 - 3452

   

4. Metabolic diversity of tumor-infiltrating T cells as target for anti-immune therapeutics

   • Peipei Li
   • Fangchao Li
   • Jingjing Li

   Review 21 September 2023 Pages: 3453 - 3460

   

5. BTK inhibition potentiates anti-PD-L1 treatment in murine melanoma: potential role for MDSC modulation in immunotherapy

   • Steven H. Sun
   • Colin D. Angell
   • William E. Carson III

   Research 02 August 2023 Pages: 3461 - 3474

   

6. Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections

   • C. Schmitt
   • E. P. Hoefsmit
   • L. M. Heinzerling

   Research Open access 22 August 2023 Pages: 3475 - 3489

   

7. Systemic administration of STING agonist promotes myeloid cells maturation and antitumor immunity through regulating hematopoietic stem and progenitor cell fate

   • Tianxiao Xu
   • Jie Dai
   • Jun Guo

   Research 07 August 2023 Pages: 3491 - 3505

   

8. Deciphering the immune reaction leading to spontaneous melanoma regression: initial role of MHCII⁺ CD163⁻ macrophages

   • Fany Blanc
   • Nicolas Bertho
   • Armelle Prévost-Blondel

   Research Open access 01 August 2023 Pages: 3507 - 3521

   

9. Role of single-cell ferroptosis regulation in intercellular communication and skin cutaneous melanoma progression and immunotherapy

   • Binyu Song
   • Yixuan Peng
   • Baoqiang Song

   Research 28 August 2023 Pages: 3523 - 3541

   

10. Preferential B cell differentiation by combined immune checkpoint blockade for renal cell carcinoma is associated with clinical response and autoimmune reactions

    • Koki Uehara
    • Kenro Tanoue
    • Eishi Baba

    Research 07 August 2023 Pages: 3543 - 3558

    

11. HLA-B*44 and the Bw4-80T motif are associated with poor outcome of relapse-preventive immunotherapy in acute myeloid leukemia

    • Hana Komic
    • Alexander Hallner
    • Fredrik B. Thorén

    Research Open access 19 August 2023 Pages: 3559 - 3566

    

12. A novel agonist of 4-1BB costimulatory receptor shows therapeutic efficacy against a tobacco carcinogen-induced lung cancer

    • Ayse Ece Gulen
    • Rakesh Rudraboina
    • Esma S. Yolcu

    Research 22 August 2023 Pages: 3567 - 3579

    

13. Thrombotic risk of platinum combination chemotherapy with and without immune checkpoint inhibitors for advanced non-small cell lung cancer: a nationwide inpatient database study

    • Chikako Iwai
    • Taisuke Jo
    • Hideo Yasunaga

    Research Open access 04 August 2023 Pages: 3581 - 3591

    

14. Reovirus combined with a STING agonist enhances anti-tumor immunity in a mouse model of colorectal cancer

    • Naomi Sugimura
    • Eiji Kubota
    • Hiromi Kataoka

    Research 01 August 2023 Pages: 3593 - 3608

    

15. Transarterial interventional therapy combined with tyrosine kinase inhibitors with or without anti-PD-1 antibodies as initial treatment for hepatocellular carcinoma with major portal vein tumor thrombosis: a single-center retrospective study

    • Wenchang Yu
    • Weifu Liu
    • Xiaolong Wang

    Research 11 August 2023 Pages: 3609 - 3619

    

16. Th1 cytokines in pediatric acute lymphoblastic leukemia

    • Sarah Schober
    • Jennifer M. Rottenberger
    • Manon Queudeville

    Research Open access 23 August 2023 Pages: 3621 - 3634

    

17. Comparison of the effectiveness of chemotherapy combined with immunotherapy and chemotherapy alone in advanced biliary tract cancer and construction of the nomogram for survival prediction based on the inflammatory index and controlling nutritional status score

    • Zhengfeng Zhang
    • Dazhen Wang
    • Changjie Lou

    Research Open access 05 September 2023 Pages: 3635 - 3649

    

18. Intravenous injection of tumor extracellular vesicles suppresses tumor growth by reducing the regulatory T cell phenotype

    • Sanshiro Kobayashi
    • Naoyuki Kondo
    • Makoto Naganuma

    Research 19 August 2023 Pages: 3651 - 3664

    

19. Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study

    • Ondřej Fiala
    • Sebastiano Buti
    • Matteo Santoni

    Research 07 September 2023 Pages: 3665 - 3682

    

20. Nomogram for predicting the prognosis of metastatic colorectal cancer patients treated with anti-PD1 therapy based on serum lipids analysis

    • Bijing Xiao
    • Hui Ouyang
    • Yan Huang

    Research Open access 17 August 2023 Pages: 3683 - 3692

    

21. Reconstructing the immunosenescence core pathway reveals global characteristics in pan-cancer

    • Yakun Zhang
    • Yue Sun
    • Xia Li

    Research 22 August 2023 Pages: 3693 - 3705

    

22. Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study

    • Melissa Bersanelli
    • Alessio Cortellini
    • Sebastiano Buti

    Research Open access 28 August 2023 Pages: 3707 - 3716

    

23. Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis

    • Jiashuo Chao
    • Shanshan Wang
    • Haitao Zhao

    Research 03 October 2023 Pages: 3717 - 3726

    

24. Combination therapy with dendritic cell loaded-exosomes supplemented with PD-1 inhibition at different time points have superior antitumor effect in hepatocellular carcinoma

    • Chunxiao Chang
    • Yanqing Pei
    • Shengbin Shi

    Research 04 September 2023 Pages: 3727 - 3738

    

25. Anti-CD79b/CD3 bispecific antibody combined with CAR19-T cells for B-cell lymphoma treatment

    • Wei-Wei Zheng
    • Hang Zhou
    • Cai-Wen Duan

    Research 14 September 2023 Pages: 3739 - 3753

    

26. Prognostic impact of soluble PD-L1 derived from tumor-associated macrophages in non-small-cell lung cancer

    • Koji Teramoto
    • Tomoyuki Igarashi
    • Yataro Daigo

    Research Open access 30 August 2023 Pages: 3755 - 3764

    

27. Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer

    • Shinsuke Ogusu
    • Yuhei Harutani
    • Ryo Ariyasu

    Research Open access 28 August 2023 Pages: 3765 - 3772

    

28. Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1

    • Sung Soo Mun
    • Jeremy Meyerberg
    • David A. Scheinberg

    Research 27 August 2023 Pages: 3773 - 3786

    

29. PD-L1-expressing cancer-associated fibroblasts induce tumor immunosuppression and contribute to poor clinical outcome in esophageal cancer

    • Kento Kawasaki
    • Kazuhiro Noma
    • Toshiyoshi Fujiwara

    Research Open access 05 September 2023 Pages: 3787 - 3802

    

30. Leptin-mediated meta-inflammation may provide survival benefit in patients receiving maintenance immunotherapy for extensive-stage small cell lung cancer (ES-SCLC)

    • Emanuele Vita
    • Alessio Stefani
    • Emilio Bria

    Research Open access 05 September 2023 Pages: 3803 - 3812

    

31. Targeting GD2 after allogeneic SCT: effector cell composition defines the optimal use of ch14.18 and the bispecific antibody construct NG-CU (GD2-CD3)

    • A.-M. Arendt
    • F. Heubach
    • P. Lang

    Research Open access 24 September 2023 Pages: 3813 - 3824

    

32. GK-1 effectively reduces angiogenesis and prevents T cell exhaustion in a breast cancer murine experimental model

    • Juan A. Hernández-Aceves
    • Jacquelynne Cervantes-Torres
    • Edda Sciutto

    Research Open access 22 September 2023 Pages: 3825 - 3838

    

33. Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma

    • Lisa May Ling Tachiki
    • Daniel S. Hippe
    • Shailender Bhatia

    Research Open access 21 September 2023 Pages: 3839 - 3850

    

34. Radiation-induced dormancy of intracerebral melanoma: endotoxin inflammation leads to both shortened tumor dormancy and long-term survival with localized senescence

    • Sharif M. Ridwan
    • Rose Emlein
    • Henry M. Smilowitz

    Research Report 23 August 2023 Pages: 3851 - 3859

    

35. Pretreatment blast-to-lymphocyte ratio as a prognostic marker for CD19/CD3-bispecific T cell-engaging antibodies (blinatumomab) treatment against relapsed or refractory B-precursor acute lymphoblastic leukemia

    • Yutaka Shimazu
    • Toshio Kitawaki
    • Akifumi Takaori-Kondo

    Brief Report 07 August 2023 Pages: 3861 - 3865

    

36. Immune profile of patients with peritoneal carcinomatosis selected for CRS-HIPEC therapy

    • Julia Kleber
    • Jordi Yang Zhou
    • Jens M. Werner

    Brief Report Open access 14 August 2023 Pages: 3867 - 3873